Welsh decision-makers approve funding of cannabidiol (Epidyolex®) for TSC-related refractory epilepsy, allowing access to the medicine in Wales

The Welsh Government has today (Friday 10 December) approved a recommendation from the All-Wales Medicines Strategy Group (AWMSG) that cannabidiol (brand name Epidyolex®) is funded within Wales for TSC-related refractory epilepsy, meaning that people living with TSC in Wales will be able to access

Scottish Medicines Consortium approves cannabidiol (Epidyolex®) for TSC-related refractory epilepsy, meaning medicine will be available in Scotland

Decision-makers in Scotland have today (Monday 7 February 2022) approved Epidyolex (generic name ‘cannabidiol’) to treat epilepsy-related Tuberous Sclerosis Complex (TSC). The news means that the TSC community in Scotland will be able to access this important new medicine from May 2022 (within 90